recombitek c8 formulation: each ml of reconstituted vaccine (dose) contains: canine distemper virus recombinant cp258 (onderstepoort strain).............> 10^6.4 tcid50 canine adenovirus type 2 (toronto a/26/61 strain)...............> 10^4.3 tcid50 canine parvovirus (780916 strain).................> 10^3.3 faid50 canine parainfluenza virus (d-008 strain).................> 10^3.9 tcid50 leptospira interrogans ser. canicola (1503 p4 strain)..................> 200 ftu leptospira interrogans ser. icterohaemorrhagiae (st1518 strain)..................> 200 ftu leptospira interrogans ser. grippotyphosa (sc4397 strain)..................> 300 ftu leptospira interrogans ser. pomona (t262 strain)..................> 300 ftu tcid-tissue culture infective dose faid. fluorescent antibody indoctive dese ftu-formazin turbidity units lyophilized powder for injection (im/sc)
boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - modified live recombinant canine distemper virus (cdv) , canine adenovirus type 2 (cav-2) , canine parvovirus (cpv) , canine parainfluenza virus (cpiv) vaccine , inactivated leptospira interrogans ser. canicola , l. interrogans ser. icterohaemorrhagiae , l. interrogans ser. grippotyphosa , l. interrogans ser. pomona vaccine (vet.) - lyophilized powder for injection (im/sc) - formulation: each ml of reconstituted vaccine (dose) contains: canine distemper virus recombinant cp258 (onderstepoort strain).............> 10^6.4 tcid50 canine adenovirus type 2 (toronto a/26/61 strain)...............> 10^4.3 tcid50 canine parvovirus (780916 strain).................> 10^3.3 faid50 canine parainfluenza virus (d-008 strain).................> 10^3.9 tcid50 leptospira interrogans ser. canicola (1503 p4 strain)..................> 200 ftu leptospira interrogans ser. icterohaemorrhagiae (st1518 strain)..................> 200 ftu leptospira interrogans ser. grippotyphosa (sc4397 strain)..................> 300 ftu leptospira interrogans ser. pomona (t262 strain)..................> 300 ftu tcid-tissue culture infective dose faid. fluorescent antibody indoctive dese ftu-formazin turbidity units
innovax-ilt formulation: each dose contains: recombinant marek's disease virus (hvt fc-126 strain......... > 2248 pfu infectious laryngotracheitis virus (d and i glycoprotein, 138 strain) pfu - plaque forming unit suspension for injection (in-ovo/sc)
msd animal health (phils.), inc.; distributor: n.a. - live recombinant marek's disease (md) virus , infectious laryngotracheitis (ilt) virus vaccine (vet.) - suspension for injection (in-ovo/sc) - formulation: each dose contains: recombinant marek's disease virus (hvt fc-126 strain......... > 2248 pfu infectious laryngotracheitis virus (d and i glycoprotein, 138 strain) pfu - plaque forming unit
purevax felv 1 dose of 1ml or 0.5 ml contains felv recombinant canarypoxvirus (vcp97-10˄7.2ccid50 suspension for injection (sc)
boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - feline leukemia of felv recombinant canarypox virus vaccine (vcp97) - suspension for injection (sc) - 1 dose of 1ml or 0.5 ml contains felv recombinant canarypoxvirus (vcp97-10˄7.2ccid50
vaxxitek hvt + ibd + nd formulation: each dose contains: marek's disease virus, serotype 3, vhvt310 (recombinant hvt, fc-126 strain) ............... >5696 pfu infectious bursal disease viral protein 2 newcastle disease virus fusion (f) protein, genotype viid pfu - plaque forming unit suspension for injection (in-ovo/sc)
boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - live recombinant marek's disease (md) virus , infectious bursal disease (ibd) virus , newcastle disease (nd) virus vaccine (vet.) - suspension for injection (in-ovo/sc) - formulation: each dose contains: marek's disease virus, serotype 3, vhvt310 (recombinant hvt, fc-126 strain) ............... >5696 pfu infectious bursal disease viral protein 2 newcastle disease virus fusion (f) protein, genotype viid pfu - plaque forming unit
shingrix recombinant varicella zoster virus glycoprotein e antigen vaccine 50 micrograms powder vial and suspension vial for suspension for injection
glaxosmithkline australia pty ltd - recombinant varicella zoster virus glycoprotein e antigen, quantity: 50 microgram - injection, powder for - excipient ingredients: sucrose; monobasic sodium phosphate dihydrate; dibasic potassium phosphate; polysorbate 80 - shingrix is indicated for the prevention of herpes zoster (hz) and post-herpetic neuralgia in: - adults 50 years of age or older; - adults 18 years of age or older at increased risk of hz.
pegintron
schering-plough labo n.v. - peginterferon alfa-2b - powder lyophilized for solution for injection - 120mcg/0,5ml
pegintron powder lyophilized for solution for injection
schering-plough labo n.v. - peginterferon alfa-2b - powder lyophilized for solution for injection - 120mcg/0,5ml
pegintron
schering-plough labo n.v. - peginterferon alfa-2b - powder lyophilized for solution for injection - 50mcg/0,5ml
pegintron powder lyophilized for solution for injection
schering-plough labo n.v. - peginterferon alfa-2b - powder lyophilized for solution for injection - 50mcg/0.5ml
pegintron
schering-plough labo n.v. - peginterferon alfa-2b - powder lyophilized for solution for injection - 80mcg/0,5ml